

Siemens Healthcare Diagnostics Inc.

Urgent Field Safety Notice

DC-18-02.A.OUS April 2018

$\operatorname{Dimension}^{\operatorname{@}}\operatorname{clinical}\operatorname{chemistry}\operatorname{system}\operatorname{and}\operatorname{Dimension}\operatorname{Vista}^{\operatorname{@}}\operatorname{System}$

Gentamicin (GENT) Flex® reagent cartridge

Potential Inaccuracy at the low end of the Analytical Measurement Range

Our records indicate that your facility may have received the following products:

Table 1. Dimension and Dimension Vista Affected Products:

Assay	Catalog Number	Siemens Material Number	Lot Number	First Shipment Date	Expiration Date
Dimension GENT	DF12	10444927	EB8115 BB8159 FB8275	2017-05-30 2017-07-24 2017-11-08	2018-04-25 2018-06-08 2018-10-02
Dimension Vista GENT	K4012	10445120	17135BC 17150BF 17159BD 17178AC 17269BD 17312BB	2017-06-12 2017-07-03 2017-07-19 2017-08-08 2017-11-02 2017-12-12	2018-05-15 2018-05-30 2018-06-08 2018-06-27 2018-09-26 2018-11-08

Reason for Field Action

Siemens Healthcare Diagnostics has confirmed Dimension Gentamicin (GENT) lot BB8159 may exhibit inaccuracy for Quality Control (QC) and patient samples at the low end of the Analytical Measurement Range. Maximum negative bias of 100% and 48% were observed for patient samples at 0.9 μ g/mL [1.94 μ mol/L] and 1.9 μ g/mL [4.1 μ mol/L], respectively. Patient samples at \geq 2.6 μ g/mL [5.62 μ mol/L] did not show a bias. The bias is due to the calibration curve not showing separation between the Level 1 and Level 2 calibrators.

Siemens investigated all other in-date Dimension and Dimension Vista GENT reagent for similar issues. It was determined that the GENT reagent lots listed in Table 1 show similar issues and Siemens predicts the separation between Level 1 and Level 2 calibrators will continue to degrade over time. At the present time, you may not detect an issue with the eight additional lots.

Risk to Health

The negative bias observed for patient, QC, and calibrator samples, when using any of the listed lots, has the potential to impact the interpretation of gentamicin results during therapeutic monitoring at concentrations up to approximately 2.5 μ g/mL [5.4 μ mol/L]. Gentamicin treatment would be correlated with clinical presentation and closely monitored. Siemens is not recommending a review of previously generated results.

Actions to be Taken by the Customer

- Inspect stock, discontinue use of and discard the Dimension and Dimension Vista GENT lots listed in Table 1.
- Please review this letter with your Medical Director.
- Review your inventory of these products to determine your laboratory's replacement needs and to provide information to Siemens for reporting to the regulatory authorities.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the product listed in Table 1, immediately contact your local Siemens Customer Care Center or your local Siemens Technical Support Representative.

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens Technical Support Representative.

Dimension and Dimension Vista are trademarks of Siemens Healthcare Diagnostics.

FIELD CORRECTION EFFECTIVENESS CHECK Dimension and Dimension Vista Gentamicin Reagent Potential Inaccuracy at the low end of the Analytical Measurement Range

This response form is to confirm receipt of the enclosed Siemens Healthcare Diagnostics Urgent Field Safety Notice, DC-18-02.A.OUS, dated April 2018 regarding Dimension or Dimension Vista Gentamicin Reagent with Potential Inaccuracy at the low end of the Analytical Measurement Range. Please read each question and indicate the appropriate answer.

Fax this completed form to Siemens Healthcare Diagnostics at the fax number provided at the bottom of this page.

I have read and underst- instructions provided in t			tood the Urgent Field Safety Notice this letter.	Yes □ No □			
Do you now have any a check inventories before			affected Gentamicin lots on hand? Please Yes re answering.				
			estion above is yes, please complete the the quantity of affected product in your ment product required.	e			
Dimension or Dimension Vista [®] Gentamicin lots			Quantity of Affected Product in inventory that has been discarded	Replacement Quantity Required			
N	ame	of person completing qu	estionnaire:				
	itle:						
Institution:		ion:	Instrument Serial Number:				
S	treet						
_City:			State:				
Phone:		:	Country:				
Customer Sold To #:		mer Sold To #:	Customer Ship To #:				
To fax this completed form please send it to your local Siemens Technical Support Representative If you have any questions, contact your local Siemens Technical Support Representative.							